国药科技股份(08156)于2026年10月7日公布2026年9月股份变动月报。公告显示，截至2026年9月30日，公司全体股东于2024年完成股本重组后，法定注册股本总额保持在200,000,000港元，分为普通股160,000,000港元及可换股优先股40,000,000港元，面值均为0.0125港元/股。相较上月，注册股本无新增或减少。
报告期末，公司普通股已发行股份为633,693,055股，较上月底无变动，其中24.95%由公众持有；可换股优先股已发行股份为1,480,151,050股，亦与上月底持平。公司确认本月无购回、注销或库藏股活动，也无因期权行使产生的新股发行。普通股股权激励方面，2021年购股权计划期末结存的股份期权数量为4,960,000份，未发生变动。
公告显示，所有股份变动事项均已获得公司董事会正式授权批准，并按相关上市规则及适用法律法规办理。公告由执行董事郭淑仪签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.